Meta AnalysisID 6475
中成药联合四联疗法对比四联疗法治疗幽门螺杆菌阳性消化性溃疡的系统评价与贝叶斯网状Meta分析
CRD42022298444
How do different Chinese patent medicine combined with quadruple therapy impact Helicobacter pylori-positive peptic ulcers compared to quadruple therapy alone?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6475
- Evidence Id
- 15033
- Core Evidence Id
- 15033
- Source Meta Analysis Id
- 6458
- Herb2 Meta Analysis Id
- HBMA006458
- Crd Id
- CRD42022298444
- Title
- Chinese patent medicine with quadruple therapy versus quadruple therapy for helicobacter pylori-positive peptic ulcers: A Systematic Review and Bayesian Network Meta-Analysis
- Review Question
- How do different Chinese patent medicine combined with quadruple therapy impact Helicobacter pylori-positive peptic ulcers compared to quadruple therapy alone?
- Study Type Included
- Inclusion criteria: RCTs; literature in English or Chinese. Exclusion criteria: Duplicate literature; Researches on animals; Retrospective study or non-randomized controlled trials; Baselines without comparability; Unclear random sequence generation.
- Condition Being Studied
- Peptic ulcers refer to ulcerative disorders of the lower esophagus, upper duodenum, and lower stomach portions, typically classified into gastric ulcers and duodenum ulcers. PU is still a source of significant morbidity and mortality worldwide, with its complication ranging from upper gastrointestinal bleeding, gastric outlet obstruction to perforation, penetration, and gastric cancer. As epidemiological studies indicated, helicobacter pylori, a bacterium, is responsible for 70%-85% of gastric ulcers and 90%-95% of duodenal ulcers. Many countries have experienced an overall increase in the prevalence of H.pylori infection over the last 20 years. Highly recommended by the clinical guidelines, quadruple therapy is now the most standardized therapy for patients with H.pylori-positive PU. It requires two antibiotics, and a proton pump inhibitor along with bismuth. Unfortunately, the antimicrobial eradication rate of H.pylori has been declining globally. For example, clarithromycin resistance has rapidly increased in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China, and 40% in Turkey. Another concern was that quadruple therapy caused mild adverse events ranging from taste disturbance, diarrhea, nausea, to abdominal pain and dyspepsia. Meanwhile, longer treatment durations were significantly associated with a higher incidence of adverse events.
- Participant
- Inclusion criteria: Adults diagnosed with H.pylori-positive peptic ulcers without limitations on sex, race, region, or nationality. Exclusion criteria: Incongruent with the diagnosis, such as without diagnosis of H.pylori positive.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion criteria: Experimental groups received quadruple therapy combined with Chinese patent medicine (such as Weisu granule, Anweiyang capsule, Kangfuxin liquid) in either arm of treatment. Exclusion criteria: Experimental groups received only one kind of western medicine, such as proton pump inhibitors, or another traditional Chinese medicine was applied, such as Chinese herbal medicine, acupuncture, or massage.
- Comparator Control
- Inclusion criteria: Control groups received quadruple therapy. Exclusion criteria: Control groups received only one kind of western medicine, such as PPIs.
- Main Outcome
- 1) Endoscopic effective rate: The criteria to judge the healing of ulcers under gastroscope is categorized into three levels: Clinical curing refers to ulcer scar healing or traceless healing; effectiveness refers to ulcer reaches stage H1 (The ulcer is in the process of healing, the surrounding congestion and edema disappear, and the ulcer fur becomes thinner and fades, accompanied by new capillaries) or stage H2 (The ulcer continues to become shallower and smaller, and the surrounding mucosal folds concentrate to the ulcer); ineffectiveness refers to no improvement under gastroscope. Endoscopic effective rate = (the number of patients in levels of clinical curing and effectiveness after receiving treatment)/(total number of patients)× 100%. 2) H.pylori eradication rate = (the number of H.pylori-negative patients after receiving treatment)/ (total number of patients)× 100%. 3) The incidence of adverse events = (the number of adverse events from patients after receiving treatment)/ (total number of patients)× 100%. 4) Recurrence rate = (the number of recurrent patients after follow-up period)/ (total number of patients in levels of clinical curing and effectiveness after receiving treatment)× 100%.
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Bayes Theorem; China; Helicobacter pylori; Humans; Network Meta-Analysis; Nonprescription Drugs; Peptic Ulcer
- Contact
- Nian Liu [email protected]
- Organisational Affiliation
- Hubei University of Chinese Medicine
- Funding Source
- The work was supported by the Wuhan Municipal Science and Technology Bureau of Applied Basic Research Project (no.2017060201010224)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-15
- Registration Date
- 2022-01-15
- Anticipated Start Date
- 2021-11-30
- Anticipated Completion Date
- 2022-12-31
- Title Cn
- 中成药联合四联疗法对比四联疗法治疗幽门螺杆菌阳性消化性溃疡的系统评价与贝叶斯网状Meta分析
- Title En
- Chinese patent medicine with quadruple therapy versus quadruple therapy for helicobacter pylori-positive peptic ulcers: A Systematic Review and Bayesian Network Meta-Analysis
- Bilingual Status
- complete